Press Releases

Press Releases

Congratulations to Stanford Medicine on winning the 2023 Hearst Health Prize for its artificial intelligence solution that helps identify patients at risk for heart attack by scoring incidental coronary artery calcium (CAC) on non-gated chest CTs.

Predictive model generation for pre-planning a cardiac procedure now reimbursable by Medicare at approximately $1,000 per model

 

Late-Breaking Science sessions reveal revolutionary findings on severe aortic stenosis and mild-to-severe mitral regurgitation identification through innovative AI technology.

 

Aug 15, 2023 | Submitted by: Keystone Perfusion Services, PC

The company's multifaceted healthcare staffing solutions play a pivotal role in transforming patient care and elevating industry standards.

 

The agreement formally endorses Corazon’s cardiovascular accreditation.

Arineta Cardio Imaging is excited to announce the FDA 510(k) clearance of the SpotLight and SpotLight Duo family of cardiovascular CT scanners.

 

Researchers and engineers at Mayo Clinic and Ultromics developed technology that can detect HFpEF using a single A4C echocardiogram clip, to help clinicians detect a complex form of heart failure easily and accurately. 

 

The Midwest company will begin offering EchoSolv, an artificial intelligence clinical decision support platform designed to help detect severe aortic stenosis, to providers throughout the country.

 

Jun 14, 2023 | Submitted by: DASI Simulations

Precision TAVI is the first FDA-approved predictive modeling tool for medical teams planning TAVR procedures.

 

 

RecoverRite’s Online Heart Learning Center to feature ACC’s CardioSmart patient tools and resources.

PulseAI, a leader in the development of cutting-edge AI-powered ECG software, has released the results of a clinical study that has shown the superiority of its deep learning AI over the Apple Watch ECG algorithm in the detection of atrial fibrillation.

 

NAPLES, Fla. – February 20, 2023   The NCH Healthcare System is proud to announce a $20 million naming gift from the Rooney Foundation, which is the philanthropic arm of the former U.S. Representative for Florida's 19th congressional district and his wife, Francis and Kathleen Rooney.  In recognition of increasing their $8 million pledge announced last July, the entire cardiac program across NCH Healthcare System will be renamed “The Rooney Heart Institute.”

NAPLES, Fla. – February 21, 2023   On the heels of our historic $20 Million gift announcement made last week, NCH is proud to announce yet a second $20 million naming gift in as many weeks from Diana and Don Wingard.  This generous gift will provide the necessary funds to ensure that the NCH Stroke program continues to provide the highest level of care and treatment to patients in Southwest Florida.  Additionally, in recognition of the extraordinary pledge, the entire stroke program across NCH will be renamed the “Wingard Stroke Institute.”

When using this service, patients have the ability to upload and share data without limitations. From radiology CDs to PDFs or JPG files, patients can use their smartphone connected to the Patient Image Exchange app and upload images, share lab results, immunizations records, nurses’ notes, dental images and much more.

 

Ancora Heart has hired senior financial leader David J. Tucker as its chief financial officer. This is the company's second C-suite hire in 2022, following the addition of Mark Miles as chief commercial officer in June.

Geneticure, a global leader in the genetic variability of response to hypertension treatments, presented data at the 2022 American Heart Association Scientific Sessions meeting from a recent clinical study in which they were able to successfully predict patients who will respond to renal denervation (RDN). In addition, the Geneticure test for renal denervation also identified patients with an increase in blood pressure, following the procedure.

Long-awaited milestone gives physicians and their patients greater access to prescription cardiac arrhythmia detection solutions, including the company’s Cardea SOLO™ ECG System

Royal Philips Electronics (NYSE: PHG, AEX: PHI), today announced the completion of patient enrollment in the CHILL-MI clinical study designed to further evaluate the safety and effectiveness of the company’s InnerCool RTx endovascular cooling system in patients with ST-elevation myocardial infarction (STEMI).  

UltraSPECT, a leading provider of nuclear medicine (NM) image reconstruction technology that reduces radiopharmaceutical dose and acquisition time, announces their distribution agreement with PharmaLogic for the sale of UltraSPECT’s Cardiac and Bone imaging applications. The agreement will enable PharmaLogic to provide its hospitals and imaging centers with access to UltraSPECT’s Xpress line of products for significantly lower radiation dose with no diminished image quality. 

Four research centers will develop high-impact culturally tailored interventions aimed at lowering stroke risk among racial and ethnic minorities in the United States. Together the centers are expected to receive $40 million in funding over five years, contingent on the availability of funds from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.

Today, the Heart Rhythm Society (HRS) announces the appointment of Peng-Sheng Chen, MD, FHRS, as the new editor-in-chief of HeartRhythm, the official journal of HRS. Effective January 2014, Dr. Chen will replace Douglas Zipes, MD, FHRS, who will have served as editor-in-chief for ten years after founding the Journal in 2004.

The Heart Failure Congress 2013 promises more science than ever this year, with a record number of abstracts submitted. The congress takes place 25-28 May at the Centro de Congressos de Lisboa in Lisbon, Portugal.

Vascular Solutions, Inc. (Nasdaq:VASC) today announced that it has re-launched the Venture catheter, a deflectable-tip catheter used to provide guidewire directional control in challenging coronary and peripheral interventional procedures. The device is available immediately in the United States and expected to become available in select international markets over the next few months.

CVRx, Inc., a private medical device company, received Food and Drug Administration (FDA) investigational device exemption (IDE) approval, allowing the company to proceed with its hypertension study.

Up to 10 per cent of patients with high blood pressure are resistant to treatment, which puts them at increased risk of cardiovascular events, including heart attacks. Clinical trials show that catheter-based renal denervation reduces blood pressure in patients who do not respond to conventional drug therapy.

The first project to receive an investment from the American Heart Association’s Science & Technology Accelerator Program will be jointly developed by CytoVas, LLC and BD Biosciences, the firms announced.

Global electrophysiology devices market forecasts to reach at US$4.4 billion by 2015 at a CAGR of 9.7% during the analysis period 2009-2015. The North American segment accounts for nearly 35% of the global value while Europe claims approximately 30% of the market. Asia-Pacific is the fastest growing region with a CAGR of 10.8% driving a market value of US$1.1 billion by 2015.

Garret FitzGerald MD, FRS, chairman of the Pharmacology Department and director of the Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, has been awarded the 2013 Grand Prix Scientifique by the Institut de France.

Thomas Wang, M.D., has joined Vanderbilt as director of the Division of Cardiovascular Medicine and the physician-in-chief of the Vanderbilt Heart and Vascular Institute.

Cath/EP and interventional lab professionals wondering if their pay is competitive are being offered an objective measuring stick from a new research poll, Phoenix-based Springboard Healthcare announced.

OrbusNeich today announced that data from the REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt) study published online in JACC: Cardiovascular Interventions demonstrated that the COMBO Dual Therapy Stent met the study’s primary endpoint and was found to be effective in controlling neointimal proliferation.

The first patient in the United States has been implanted with the Boston Scientific Corporation (NYSE: BSX) next generation ImageReady™ MR Conditional pacing system in the SAMURAI clinical trial.

Carolinas HealthCare System’s Sanger Heart & Vascular Institute became the first in the world to implant a branched stent graft specifically designed for branch vessel repair of thoracic aortic aneurysms on Thursday. This is the first arch graft available in a clinical trial and both the device and surgical approach are novel.

Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Roderick de Greef will retire from the Board of Directors at the end of his current term, which ends on May 23, 2013, the date of the Company's annual shareholder meeting. Thomas F. Zenty, III will stand for election as a Class III director to fill the resulting vacant position at the upcoming annual shareholder meeting.

AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that John Kastelein, MD, Ph.D., Chairman of the department of vascular medicine and Strategic Chair of Genetics in Cardiovascular Disease at the Academic Medicine Center of the University of Amsterdam, has joined the Company as a member of the Medical Advisory Board and will be a Co-Principal Investigator in the Company's upcoming clinical trials. 

James Chen-tson Fang, M.D., has been named chief of cardiovascular medicine at the University of Utah School of Medicine and director of the cardiovascular service line at University of Utah Health Care.

eClinicalWorks®, a leader in ambulatory healthcare IT solutions, today announced that Arkansas Heart Hospital, a nationally recognized and award-winning hospital dedicated to the prevention, diagnosis and treatment of cardiovascular disease, has selected eClinicalWorks comprehensive electronic health records (EHR) solution for all of its clinic locations. Tight integration with the organization’s laboratory and cardio diagnostics systems will extend the benefits of this technology. 

Medtronic, Inc. (NYSE:MDT) today announced market release of the CardioGuide™ Implant System, a novel real-time navigation system for cardiac resynchronization therapy pacemakers and defibrillators (CRT-P and CRT-D), in the United States and Canada. The system helps physicians determine the most appropriate location for left-ventricular lead placement by generating 3-D images of the cardiac veins; enhanced software for the system will be commercially available later this year that also analyzes the motion of select cardiac vessels on the left side of the heart. Clinical studies have shown that appropriate left-ventricular lead placement may improve CRT response in heart failure patients (1,2,3).